Suzhou Juvvax Biotechnology

Suzhou Juvvax Biotechnology is a clinical-stage Chinese biopharmaceutical company specializing in the research, development, and commercialization of innovative vaccines. The company focuses on addressing significant unmet medical needs in infectious diseases and oncology, utilizing its proprietary recombinant protein expression and advanced adjuvant technology platforms. Juvvax's lead programs include a 9-valent Human Papillomavirus (HPV) vaccine and therapeutic candidates for Hepatitis B. By integrating high-efficiency manufacturing with cutting-edge immunology, the company aims to provide high-quality, accessible vaccine solutions for both the Chinese and global markets.